{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(2)"],"submitter":["Cao Y"],"funding":["Telix Pharmaceuticals","National Cancer Institute"],"journal":["Pharmaceutics"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12944229"],"repository":["biostudies-literature"],"pubmed_title":["89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma"],"pmcid":["PMC12944229"],"funding_grant_id":["K08CA249047","K08CA259626"],"pubmed_authors":["Salari K","Esfahani S","Talluto J","Blute M","Dahl D","Heidari P","Cao Y","McVeigh T","Kim J"],"additional_accession":[]},"is_claimable":false,"name":"89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma","description":null,"dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-11T03:16:51.444Z","creation":"2026-07-11T03:12:00.714Z"},"accession":"S-EPMC12944229","cross_references":{}}